REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
23 hedge funds and large institutions have $5.54M invested in REVIVA PHARMA HLDGS INC in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 5 closing their positions.
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
236% more capital invested
Capital invested by funds: $1.65M → $5.54M (+$3.89M)
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
103% more call options, than puts
Call options by funds: $1.5M | Put options by funds: $737K
35% more funds holding
Funds holding: 17 → 23 (+6)
0.09% more ownership
Funds ownership: 0.23% → 0.32% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
EMC Capital Management
Houston,
Texas
|
+$263K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$257K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$229K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$223K |
| 5 |
Two Sigma Investments
New York
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$153K |
| 2 |
VF
Virtu Financial
New York
|
-$73K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$52K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$45K |
| 5 |
Jane Street
New York
|
-$27K |
RVPH Hedge Fund Activity: Q4 2022 in Review
23 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q4 2022, worth a combined $5.54M — up 236% from $1.65M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RVPH positions and 5 closed out — a net gain of 6 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was EMC Capital Management, adding an estimated $263K. The largest seller was Citadel Advisors, exiting entirely with an estimated $153K sold.
- 23 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q4 2022, up from 17 in Q3 2022.
- Funds reported $5.54M of REVIVA PHARMA HLDGS INC stock for Q4 2022, up 236% quarter-over-quarter.
- 11 funds opened new REVIVA PHARMA HLDGS INC positions in Q4 2022 and 5 closed out, a net change of +6 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q4 2022 was EMC Capital Management, an estimated $263K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q4 2022 was Citadel Advisors, an estimated $153K sold.
Based on aggregated 13F filings for Q4 2022.